Sorin Group is a world leader in the development of medical technologies for cardiac surgery. We offer innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and also for the treatment of chronic kidney diseases. Over 4,700 employees of the Group work to provide the medical community with products and technologies to treat millions of people worldwide and improve the quality of life.
The range of devices that treat cardiovascular diseases includes:
Products that treat chronic kidney diseases include:
With a global sales network covering more than 80 countries and some 5,000 treatment centers, the Sorin Group is the world’s leading producer of devices and systems for cardiac surgery and one of the top European players in the Cardiac Rhythm Management market segment. We design, develop, engineer and produce technologically innovative and safe systems and products. The operations of the Sorin Group are organized into four areas of business:
This is an area that traditionally has been of key importance for the Group and includes two divisions – Perfusion and Blood Management Systems – which specializes in the manufacture of oxygenators and extracorporeal blood circulation systems used in cardiac surgery to keep patients alive during open heart surgery by taking over cardiac and pulmonary functions.
The division offers a complete line of adult and pediatric products, as well as devices for autologous transfusion and therapeutic blood treatment and Cardiac Surgery Implantable Devices, which specializes in the manufacture of artificial heart valves (both mechanical and tissue) and annuloplasty rings. The Sorin Group is present in these market segments through the following brands: Dideco, Sorin Biomedica Cardio, COBE Cardiovascular, Stöckert, CarboMedics and Mitroflow.
This division specializes in pacemakers, implantable defibrillators, resynchronizers, holter monitors and electrophysiology products. The Group operates in this market through two brands: ELA Medical and Sorin Biomedica CRM. With its family of ELA Medical products, the Sorin Group is one of the few organizations in the world that has the technology necessary to develop and manufacture implantable defibrillators. These highly sophisticated miniaturized machines can automatically reset the natural rhythm of the heart after arrests caused by ventricular fibrillation.
This area of business focuses on highly innovative solutions for treating cardiovascular diseases and dysfunctions of the circulatory system. The specific areas of activity are interventional cardiology (which includes coronary stents and drug-eluting stents produced with the proprietary Carbofilm technology that are currently in clinical testing); peripheral and endovascular stents for use in peripheral arteries; and blood derivative technologies, including projects in the area of stem cells and the use of erythrocytes for drug delivery purposes. The Group is present in this area of the market through its Sorin Biomedica brand.
We manufacture disposable products to treat chronic kidney diseases with h emodialysis systems. The Group is present in this segment through Bellco and Soludia, a French company that specializes in the production of concentrates used to prepare dialysis solutions. The product line includes complete systems consisting of dialysis units, hollow-fiber dialyzer filters of different types, hematic lines and solutions for dialysis therapy.
Via Borgonuovo, 14
20121 Milano, Italy